AndreaRuthHagemannMD
Obstetrics & Gynecology • Saint Louis, MOGynecologic Oncology
Gynecologic Oncology
Dr. Hagemann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110Phone+1 314-362-3181Fax+1 314-362-2893
Education & Training
University of Pennsylvania Health SystemFellowship, Gynecologic Oncology, 2008 - 2011
Washington University/B-JH/SLCH ConsortiumResidency, Obstetrics and Gynecology, 2004 - 2008- Washington University in St. Louis School of MedicineClass of 2004
Certifications & Licensure
IL State Medical License 2020 - 2026
MO State Medical License 2011 - 2025
PA State Medical License 2008 - 2012- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients Start of enrollment: 2010 Aug 01
- Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma Start of enrollment: 2016 Jan 01
- Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome Start of enrollment: 2021 Apr 09
Publications & Presentations
PubMed
- 93 citationsPositive peritoneal cytology is an independent risk-factor in early stage endometrial cancer ☆Gunjal Garg, Feng Gao, Jason D. Wright, Andrea R. Hagemann, David G. Mutch
Gynecologic Oncology. 2013-01-01 - 57 citationsFIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival.Perry W. Grigsby, Leslie S. Massad, David G. Mutch, Matthew A. Powell, Premal H. Thaker
Gynecologic Oncology. 2020-06-01 - 189 citationsRandomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology StudyDmitriy Zamarin, Robert A. Burger, Michael W. Sill, Daniel J. Powell, Heather A. Lankes
Journal of Clinical Oncology. 2020-04-10
Journal Articles
- Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian CancerIan S Hagemann, Premal H Thaker, Carolyn K McCourt, Katherine C Fuh, David G Mutch, Andrea R Hagemann, Matthew A Powell, Clinical Cancer Research
- Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous CancerIan S Hagemann, Carolyn K McCourt, Matthew A Powell, Premal H Thaker, David G Mutch, Katherine C Fuh, Andrea R Hagemann, Clinical Cancer Research
Press Mentions
Medical Students Celebrate Their Teachers, MentorsNovember 19th, 2019
Case Series Do Gynecologic Oncology Patients with Severely Diminished Renal Function and Urinary Tract Obstruction Benefit from Ureteral Stenting or Percutaneous Nephrostomy?May 12th, 2019
$11.6 Million Grant Supports Innovative Research in Endometrial Cancer – Washington University School of Medicine in St. LouisSeptember 7th, 2023- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
